bezafibrate has been researched along with simvastatin in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.17) | 18.7374 |
| 1990's | 29 (50.00) | 18.2507 |
| 2000's | 14 (24.14) | 29.6817 |
| 2010's | 12 (20.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Desager, JP; Harvengt, C; Horsmans, Y | 1 |
| Bruckert, E; De Gennes, JL; Truffert, J | 1 |
| Charleson, H; French, JK; Lewis, GR; Lintott, CJ; Maling, TJ; Nye, ER; Reuben, S; Scott, RS; Sharpe, DN; White, HD | 1 |
| Bo, M; Bonino, F; Fabris, F; Gottero, M; Molaschi, M; Neirotti, M; Pernigotti, L | 1 |
| Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Jankelow, D; Myburgh, DP; Neutel, JM; Smith, DH | 1 |
| Carlson, LA | 1 |
| Bojanovski, D; Bojanovski, M; Canzler, H; Jochim, A; Schulzeck, P | 1 |
| Bard, JM; Devulder, B; Douste-Blazy, P; Fruchart, JC; Harvengt, C; Lecerf, JM; Leclerc, V | 1 |
| Weisweiler, P | 1 |
| Galiana, J; Marchán, E; Montés, I; Pato, S | 1 |
| Duncan, A; Murphy, MJ; O'Reilly, DS; Packard, CJ; Vallance, BD | 1 |
| Branchi, A; Fiorenza, AM; Rovellini, A; Sommariva, D | 1 |
| Barbir, M; Hunt, BJ; Kehely, A; MacMahon, M; Prescott, RJ; Thompson, GR; Wray, R | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Hutchesson, AC; Jones, AF; Moran, A | 1 |
| Cummings, MH; Watts, GF | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 1 |
| Chapman, BA; Hurrell, MA; Wilson, IR | 1 |
| Barbir, M; Galloway, D; Hunt, BJ; Ilsley, C; Mitchell, A; Taylor, A; Yacoub, M | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Irsigler, H; Klein, W; Lechleitner, M; Patsch, JR; Sailer, S | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Coulter, DM | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Kesäniemi, YA | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Sánchez, RM; Verd, JC | 1 |
| Sinzinger, H | 1 |
| Beggs, PW; Clark, DW; Coulter, DM; Williams, SM | 1 |
| Gavish, D; Leibovitz, E; Rubinstein, A; Shapira, I | 1 |
| Bisicchia, A; Di Salvo, MM; Ferlito, S; Gallina, M; Mugno, F | 1 |
| Isles, CG; Paterson, JR | 1 |
| Black, DM | 1 |
| Vita, JA; Winniford, M; Yeung, AC | 1 |
| Adachi, K; Azuma, C; Hayakawa, J; Ikegami, H; Kurachi, H; Matumoto, K; Morishige, K; Murata, Y; Nishio, Y; Node, K; Ohmichi, M; Tasaka, K | 1 |
| Ishibashi, S | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Fisman, EZ; Motro, M; Tenenbaum, A | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L | 1 |
| de Vries, R; Dullaart, RP; Sluiter, WJ; van Tol, A; Voorbij, HA | 1 |
| Ahnström, J; Dahlbäck, B; de Vries, R; Dikkeschei, BD; Dullaart, RP; Kappelle, PJ; Nielsen, LB; Sluiter, WJ; van Tol, A; Wolffenbuttel, BH | 1 |
| Constantinides, A; de Vries, R; Dullaart, RP; Gautier, T; Lagrost, L; Tselepis, AD; van Leeuwen, JJ; van Pelt, LJ | 1 |
| Dallinga-Thie, GM; de Vries, R; Dikkeschei, BD; Dullaart, RP; Sluiter, WJ; van Tol, A | 1 |
| Annema, W; de Boer, JF; Dullaart, RP; Tietge, UJ; Triolo, M | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Bortoletto, MS; Petris, AJ; Souza, RK | 1 |
| Liu, QZ; Shang, J; Wang, H; Wang, LL; Zhou, J | 1 |
| Borges, IBP; Misse, RG; Shinjo, SK; Silva, MG | 1 |
| Haußmann-Vopel, S; Lehmann, C; Pavlovic, D; Wegner, A | 1 |
9 review(s) available for bezafibrate and simvastatin
| Article | Year |
|---|---|
[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
Topics: Adult; Aged; Bezafibrate; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Simvastatin | 1995 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Supplements; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Triglycerides | 2000 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
[Guideline for management of lipid metabolism].
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Primary Prevention; Risk; Simvastatin | 2002 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.
Topics: Adult; Aged; Aged, 80 and over; Bezafibrate; Dermatomyositis; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Immunosuppressive Agents; Male; Middle Aged; Polymyositis; Remission Induction; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2018 |
24 trial(s) available for bezafibrate and simvastatin
| Article | Year |
|---|---|
Effects of combined bezafibrate-simvastatin appraised in healthy subjects.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lipids; Lovastatin; Male; Muscles; Pain; Phosphatidylcholine-Sterol O-Acyltransferase; Simvastatin | 1992 |
[Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; New Zealand; Simvastatin | 1991 |
Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Cholesterol; Female; Hemostasis; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin; Sterol O-Acyltransferase | 1988 |
Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholesterol; Delayed-Action Preparations; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Receptors, LDL; Simvastatin | 1995 |
Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Topics: Analysis of Variance; Bezafibrate; Colestipol; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor VII; Factor VIII; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1994 |
[Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
Topics: Aged; Bezafibrate; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome | 2000 |
Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy.
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Postmenopause; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Aryldialkylphosphatase; Bezafibrate; Carboxylic Ester Hydrolases; Case-Control Studies; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Male; Middle Aged; Simvastatin; Statistics as Topic | 2009 |
Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
Topics: Apolipoproteins; Apolipoproteins M; Bezafibrate; Blood Pressure; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipocalins; Male; Middle Aged; Placebos; Simvastatin | 2010 |
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Bezafibrate; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 2012 |
Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
Topics: Adult; Bezafibrate; Case-Control Studies; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Simvastatin | 2012 |
Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Topics: Anti-Inflammatory Agents; Antioxidants; Bezafibrate; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin | 2014 |
25 other study(ies) available for bezafibrate and simvastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin | 1990 |
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles].
Topics: Bezafibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Simvastatin | 1988 |
Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Drug Interactions; Female; Fenofibrate; Humans; Hypolipoproteinemias; Lovastatin; Male; Middle Aged; Probucol; Simvastatin | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Variation in the estimation of gallbladder volume using the sum-of-cylinders method.
Topics: Bezafibrate; Body Mass Index; Gallbladder; Gallbladder Emptying; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Reproducibility of Results; Simvastatin; Ultrasonography | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Reasons for stopping drugs are monitored in New Zealand.
Topics: Adverse Drug Reaction Reporting Systems; Bezafibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; New Zealand; Product Surveillance, Postmarketing; Simvastatin | 1996 |
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane | 1997 |
Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
Topics: Acyltransferases; Animals; Atorvastatin; Bezafibrate; Cholesterol; Diacylglycerol O-Acyltransferase; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lipids; Liver; Male; Phospholipids; Pyrroles; Rabbits; Simvastatin; Triglycerides | 1998 |
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hypertension; Lipids; Male; Myocardial Ischemia; New Zealand; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Random Allocation; Retrospective Studies; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome | 1999 |
Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients after vasoactive and lipid-lowering treatment.
Topics: Arterial Occlusive Diseases; Bezafibrate; E-Selectin; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Vasoconstrictor Agents | 2000 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Humans; Male; Myocardial Infarction; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Simvastatin; Survival Rate; Treatment Outcome | 2001 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.
Topics: Bezafibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Simvastatin | 2004 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin | 2008 |
[Public sector participation in the supply of dyslipidemia medication in a population-based study].
Topics: Adult; Aged; Bezafibrate; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Interviews as Topic; Male; Middle Aged; Prevalence; Public Sector; Simvastatin | 2016 |
Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice.
Topics: Animals; Behavior, Animal; Bezafibrate; Depression; Diet, High-Fat; Glucose Tolerance Test; Hindlimb Suspension; Hippocampus; Male; Mice; Serotonin; Signal Transduction; Simvastatin; Stress, Psychological; Swimming; Tryptophan | 2017 |
Impact of lipid modulation on the intestinal microcirculation in experimental sepsis.
Topics: Animals; Anti-Inflammatory Agents; Bezafibrate; Blood Flow Velocity; Capillaries; Cytokines; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intestines; Intravital Microscopy; Leukocyte Rolling; Lipid Metabolism; Lipopolysaccharides; Lipoproteins, HDL; Male; Microcirculation; Microscopy, Fluorescence; Microscopy, Video; Rats, Inbred Lew; Regional Blood Flow; Sepsis; Simvastatin | 2018 |